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Summary.-Peripheral plasma levels of immunoreactive 6-oxo-PGF1a, the stable
hydrolysis product of prostacyclin, were significantly higher in female patients
with tumours of the genital tract than in normal controls. In the groups with malig-
nant tumours, these high levels declined after operation and/or radiotherapy if the
tumour responded to treatment. In patients who did not respond to treatment or
with tumour recurrence, levels of plasma 6-oxo-PGF,a remained high or even rose
further. Benign gynaecological tumours were also associated with significantly
raised plasma 6-oxo-PGFjoc levels, and these fell to normal levels immediately on
surgical removal of the tumour. Possible reasons for these alterations are described.
Further investigations are warranted to see whether serial measurements of plasma
6-oxo-PGF,a. could be used as a prognostic index for the clinical status of patients
with gynaecological tumours.
THE PRESENCE of prostaglandins in
virtually all cell types so far studied and
their potent biological activity has promp-
ted their study in patients with malignant
tumours. Increased synthesis of prosta-
glandins by tumour tissues of thyroid
(Williams et al., 1968), phaeochromo-
cytoma and bronchus (Sandler et al.,
1968), kidney (Cummings & Robertson,
1977), breast (Bennett et al., 1975) and
endometrium (Singh et al., 1976; Willman
et al., 1976) have been described. Raised
plasma levels of prostaglandins or their
metabolites have been measured in the
peripheral circulation and across the
tumour bed in patients with both genital-
tract and breast tumours (Sanders et al.,
1980; Powles et al., 1977; Stamford et
al., 1980, derived from Mortel et al., 1977).
This has led to the suggestion that plasma
prostaglandin measurements might be a
potentially useful tumour marker.
Prostacyclin (PGI2), a very potent
vasodilator and anti-platelet-aggregating
agent, is the major product of the cyclo-
oxygenase enzyme pathway in a variety
of tissues (Moncada & Vane, 1979). Unlike
the primary prostaglandins, PGI2 is
neither metabolized by the lung (Hawkins
et al., 1978) nor is it formed in vitro during
blood sampling and preparation. Prosta-
cyclin is spontaneously hydrolysed to 6-
oxo-PGF,a, a metabolite which has been
used extensively as a measure of PGI2
production. Khan et al. (1980) have
found significantly raised levels of plasma
6-oxo-PGF,a in patients with malignant
prostatic disease. In this preliminary
study we have measured plasma 6-oxo-
PGF,cx in patients with a variety of
gynaecological tumours, and examined
serial changes after surgery and/or chemo-
therapy or radiotherapy and at short-
term follow-up.
PATIENTS AND METHODS
Twenty patients formed the control group.
Ten of these underwent major gynaecological
surgery for conditions other than a tumour,
and 10 were being treated medically for
minor problems such as vaginitis.
Of the 52 patients with gynaecologicalPLASMA 6-OXO-PGFia AND GYNAECOLOGICAL TUMOURS
tumours, 15 had benign tumours and 37
malignant tumours. Of the benign-tumour
group 12 had uterine fibroids and 3 had an
ovarian cyst. The malignant group consisted
of carcinoma of the ovary (17), carcinoma of
the cervix (16) and carcinoma of the uterus
(4).
Venous blood (5 ml) was taken from the
antecubital vein into EDTA and immediately
centrifuged at 1500 g for 10 min at 4°C.
-Plasma was separated and stored at -20°C.
Levels of 6-oxo-PGFla were assayed by
specific radioimmunoassay (Myatt et al.,
1981) within 4 weeks of collection. Collec-
tion of blood into indomethacin gave similar
values to that collected in EDTA. There-
fore, artefactual in vitro formation of PGI2
did not influence the results. As radio-
immunoassay cannot be entirely specific,
the results are expressed as immuno-
reactive plasma 6-oxo-PGFlo equivalents,
and serial changes in immunoreactive 6-
oxo-PGFlx were measured. Where applicable,
blood samples were collected as follows:
(i) 24 h before operation or start of radio-
therapy.
(ii) On the 7th or 8th postoperative day.
(iii) During the 6th or 7th week after
surgery or radiotherapy.
(iv) 12 weeks after start ofradiotherapy.
All samples were collected between 10:00 and
12:00. None of the patients were given any
analgesics known to inhibit prostaglandin
synthesis (e.g. aspirin and other non steroidal
anti-inflammatory drugs).
The statistical differences between mean
6-oxo-PGFlo levels of the various groups
was assessed by Wilcoxon's rank sum test or,
within the same group, by Wilcoxon's
signed rank testfornonparametric statistics.
RESULTS
The plasma immunoreactive 6-oxo-
PGF,cx levels in the various study groups
are shown in Tables I & II.
Control group
Plasma 6-oxo-PGFloz levels of 93 + 32
pg/ml (mean + s.d.) in the control group
were similar to those previously measured
in normal subjects (Myatt et al., 1981);
the mean postoperative value of 103 + 30
pg/ml found in the 10 patients who
underwent major gynaecological surgery
for a non-malignant condition was not
significantly different from that of the
control values.
Benign tumour group
The pre-operative plasma 6-oxo-PGF1o,
levels were significantly higher (P < 0.05)
in this group than in the control group.
After removal of the tumour, high 6-oxo-
PGF,ox levels fell to the normal range in
all the patients (Fig. 1). With both
fibroids and ovarian cysts there appeared
to be a direct relationship between the
size of the tumour as assessed clinically
and the increase in plasma 6-oxo-PGF,oc
levels.
Malignant tumour group
Carcinoma of the cervix.-In 11 patients
with Stage 0 carcinoma of the cervix,
TABLE I.-Plasma immunoreactive 6-oxo-PGF1ot in patients with gynaecological tumours
Tumour type
Normal
Non-malignant (n = 15)
Fibroids (n= 12)
Ovarian cyst (n =3)
Median age
(range)
39 (56)
42 (31)
Mean +s.d. plasma 6-oxo-PGFlx equivalents (pg/ml)
Pre-op Post-op (post therapy)
93 + 32 103 + 30 Follow-up
181 + 120* ** 114+64 91+31
(n=10)
181+136 * 109+ 71 88+ 30
(n=9)
183 + 29 132 + 13
Ca cervix (n-16) 45 (40) 215+103** ** 122+59 ** 91+44
(n= 13)
Stage 0 (n=11) 228+87** ** 113+56 * 94+47
Stage I-IV (n=5) 187+129 142+60 80+28
Postoperative samples were taken 7-8 days after operation and follow-up samples at 6-7 weeks. Cancer of
the cervix (Stage I-IV) samples were taken at diagnosis, 6 weeks after start ofradiotherapy and at 12 weeks.
Significance of differences * P<0 05, ** P<0-01, *** P<0-001. Differences between columns are by
Wilcoxonsignedrank test andP values attached to means refer to the difference from the normalpre-operative
value evaluated by the Wilcoxon rank sum test for nonparametric analysis.
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TABLE II.-Plasma immunoreactive 6-oxo-PGFo1 inpatients with carcinoma of the ovary
and uterus
Mean +s.d. plasma 6-oxo-PGF1oe equivalents (pg/ml)
Median age , <
Outcome (range) Pre-op Post-op Follow-up
(a) Responders (n=15) 57-5 (40) 267+55** ** 199+38** ** 141+72
(n= 10)
(b) Non-responders (n= 6) 71-5 (15) 202 + 103** 175+123 225+66***
Postoperative samples were taken at 7-8 days after operation and follow-up samples at 6-7 weeks.
Significance of differences * P<0 05, ** P<0-01, *** P<0-001, as in Table I.
plasma 6-oxo-PGF,a levels were sigii-
ficantly raised (P<0001) at the time of
diagnosis (Table I). After a total hysterec-
tomy and during subsequent follow-up,
plasma 6-oxo-PGF1a levels were com-
parable to those of controls. The 5
patients with Stage I-IV disease had
raised levels of plasma 6-oxo-PGF1oz but
unrelated to Stage. The rise was not
statistically significant, perhaps due to
the small number of patients. After
radiotherapy all these patients improved
clinically, whilst their plasma 6-oxo-
PGF1oz levels had fallen slightly by 6
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Fia. 1.-Plasma 6-oxo-PGFla in patients
with benign gynaecological tumours.
, uterine fibroids; ---, ovarian
cysts.
weeks, and to the normal range by 3
months (80 + 28 pg/ml: Table I).
Carcinoma of the ovary and uterus.-
There were 17 patients with carcinoma of
the ovary in this group, with disease
ranging from Stage Ia to IV (FIGO), and
4 with carcinoma of the uterus.
The changes in plasma 6-oxo-PGF,cx
levels in both groups of patients were
dependent on the clinical outcome. In
view of the few carcinomas of the uterus,
both groups were combined for analysis.
Pre-operative plasma 6-oxo-PGF,a levels
were significantly high, both those respon-
sive and those irresponsive to therapy
(Table II) but with no significant
difference between these two groups.
Responders
In 12 patients with carcinoma of the
ovary the operation was total abdominal
hysterectomy, bilateral salpingo-oophorec-
tomy, removal of tumour and omen-
tectomy, followed by chemotherapy. All
12 responded to treatment and are alive,
and their 6-oxo-PGF,ox levels had fallen
considerably after surgery and at follow-
up (Fig. 2). Of the 7 cases available for
follow-up, 3 were studied more closely.
In these patients plasma 6-oxo-PGF,a
levels fell postoperatively (Fig. 2) but a
subsequent rise was seen while they were
awaiting chemotherapy. Once chemo-
therapy was started, plasma 6-oxo-PGF,a
levels fell, with concurrent clinical im-
provement in all patients.
Three of the 4 patients with carcinoma
of the uterus were operable, responded to
radiotherapy, and are alive and well.
Both postoperatively and after radio-
L) .
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therapy, plasma 6-oxo-PGFloc levels fell
to normal. In the combined group of
responsive patients, significant reductions
4501
of plasma 6-oxo-PGFjoc occurred in the
postoperative andfollow-up periods (Table
II). Although the levels were still signi-
ficantly higher than normal postopera-
tively, they hadfallento withinthenormal
range at follow-up.
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FIG. 2.-Plasma 6-oxo-PGF1ainpatients with
carcinomaofthe ovary. , responders;
-- -, non-responders; *, chemotherapy;
*, radiotherapy.
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FiG. 3.-Plasma 6-oxo-PGFlos in
with carcinoma of the cervix.
Stage 0; --, Stages I-IV.
Follow-up
patients
Non-responders
Five patients with carcinoma of the
ovary and one with carcinoma of the
uterus were found to be inoperable.
None of these responded to chemotherapy
and all subsequently died. The mean
plasma 6-oxo-PGF1oc levels were signifi-
cantly raised before laparotomy (Table
II), were not significantly affected by
chemotherapy, and were still significantly
above normal atfollow-up. This contrasted
with the group of patients who responded
to therapy, in all of whom plasma 6-oxo-
PGF10a fell.
DISCUSSION
Plasma 6-oxo-PGF1oz levels in the
control group of patients were not altered
by major surgery. To our knowledge no
other study has shown an increase in
prostaglandin production associated with
a benign tumour. The apparent relation-
ship between benign tumour size (fibroid
or ovarian cyst) and plasma 6-oxo-PGF1o,
suggested either that the tumour pro-
duced and released PG12 into the peri-
pheral circulation or that increased PGI2
production may be associated with the
increased vascular supply to these tu-
mours. Plasma 6-oxo-PGFlox levels rise
during normal pregnancy, perhaps in
association with the increased uterine
vascularity (Bolton et al., in press).
Primary prostaglandin concentrations
are increased in plasma (Sanders et al.,
1980), tumour tissues (Singh et al.,
1976; Willman et al., 1976) and across
the tumour bed (Stamford et al., 1980,
derived from Mortel et al., 1977) in
patients with gynaecological tumours.
The lack of PG12 metabolism by the
lung (Hawkins et al., 1978), and its
spontaneous hydrolysis in plasma to
6-oxo-PGF1x, which has a relatively
u I
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long half-life, both facilitates measure-
ment and makes plasma measurements
more meaningful than for the primary
prostaglandins.
In contrast to Sanders et al. (1980),
who measured peripheral plasma PGF, we
found no correlation between either tum-
our type or stage of differentiation and
plasma 6-oxo-PGF,ac levels. However,
other reports show a conflict over the
correlation between tumour differentia-
tion and PG production (Khan et al.,
in press; Bennett et al., uinpublished:
Rolland et al., 1980).
Plasma 6-oxo-PGF,o levels fell in
cases of carcinoma of the ovary or uterus
after surgery, or if the tumour sub-
sequently responded to chemotherapy or
radiotherapy, but rose in all patients
whose tumours did not respond to therapy.
The clinical progression of such tumours
may perhaps be monitored, though the
origin of the increased 6-oxo-PGF,ox is
uncertain. Our observations on the car-
cinoma of the ovary group suggest that
chemotherapy should be started as soon
as possible. The differences between
chemotherapy-responsive and non-respon-
sive patients with carcinoma of the ovary
suggest that a reduction of plasma 6-oxo-
PGFjjx is secondary to tumour regression
rather than a direct effect of chemo-
therapy on the prostaglandin synthetic
pathways.
The findings of significantly raised
plasma 6-oxo-PGFlcx levels in patients
with Stage 0 squamous carcinoma of the
cervix are initially surprising, in view of
the microscopic tumouirs. Rather than
producing PG12, these cells may be
releasing factors that alter PGI2 synthesis
or metabolism at other locations. Treat-
ment of Stage 0 carcinoma of the cervix
produced a more rapid fall of 6-oxo-
PGFja than in carcinoma of the ovary or
uterus. The more advanced cases of
carcinoma of the cervix (Stage I-IV)
with increased vascular involvement were
not associated with further increases in
pre-treatment plasma 6-oxo-PGF,oa levels.
The slower fall in 6-oxo-PGF1I in these
patients after radiotherapy may indicate
a slower rate of tumour regression.
However, the inflammatory response of
irradiated tissues may stimulate PGJ2
production (Tanner et al., 1981) which
masks the fall in production by tumour
tissue. Therefore in these patients plasma
6-oxo-PGF,oa may not be initially such
an accurate marker for the clinical
response of the tumour itself, though it
undoubtedly is at follow-up.
Our findings add to the weight of
evidence for increased plasma prosta-
glandin levels in cancer patients. Serial
measurements of 6-oxo-PGF,x may, with
some reservations such as treatment with
radiotherapy, provide a useful guide to
the clinical progression of the disease,
though they have to be used with caution
to diagnose malignancy. In vitro experi-
ments, more invasive sampling techniques
and a larger study are needed to clarify
the source of prostaglandin, or its possible
correlation with disease stage. The potent
vasodilator and platelet-anti-aggregation
properties of prostacyclin bring into
question its role in dissemination of
cancer.
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